|
1
|
Eisenhauer EA: Real-world evidence in the
treatment of ovarian cancer. Ann Oncol. 28 (Suppl 8):viii61–viii65.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Leung F, Diamandis EP and Kulasingam V:
Ovarian cancer biomarkers: Current state and future implications
from high-throughput technologies. Adv Clin Chem. 66:25–77.
2014.PubMed/NCBI
|
|
3
|
Doubeni CA, Doubeni AR and Myers AE:
Diagnosis and management of ovarian cancer. Am Fam Physician.
93:937–944. 2016.PubMed/NCBI
|
|
4
|
Liu HD, Xia BR, Jin MZ and Lou G: Organoid
of ovarian cancer: Genomic analysis and drug screening. Clin Transl
Oncol. 22:1240–1251. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kossaï M, Leary A, Scoazec JY and Genestie
C: Ovarian cancer: A heterogeneous disease. Pathobiology. 85:41–49.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Elias KM, Guo J and Bast RC Jr: Early
detection of ovarian cancer. Hematol Oncol Clin North Am.
32:903–914. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lisio MA, Fu L, Goyeneche A, Gao ZH and
Telleria C: High-grade serous ovarian cancer: Basic sciences,
clinical and therapeutic standpoints. Int J Mol Sci.
20(952)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bhan A, Soleimani M and Mandal SS: Long
noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Botti G, Marra L, Malzone MG, Anniciello
A, Botti C, Franco R and Cantile M: LncRNA HOTAIR as prognostic
circulating marker and potential therapeutic target in patients
with tumor diseases. Curr Drug Targets. 18:27–34. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fan CN, Ma L and Liu N: Systematic
analysis of lncRNA-miRNA-mRNA competing endogenous RNA network
identifies four-lncRNA signature as a prognostic biomarker for
breast cancer. J Transl Med. 16(264)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chao Y and Zhou D: lncRNA-D16366 Is a
potential biomarker for diagnosis and prognosis of hepatocellular
carcinoma. Med Sci Monit. 25:6581–6586. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Saeedi N and Ghorbian S: Analysis of
clinical important of LncRNA-HOTAIR gene variations and ovarian
cancer susceptibility. Mol Biol Rep. 47:7421–7427. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yan L, Zhou J, Gao Y, Ghazal S, Lu L,
Bellone S, Yang Y, Liu N, Zhao X, Santin AD, et al: Regulation of
tumor cell migration and invasion by the H19/let-7 axis is
antagonized by metformin-induced DNA methylation. Oncogene.
34:3076–3084. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mu Y, Li N and Cui YL: The lncRNA CCAT1
upregulates TGFβR1 via sponging miR-490-3p to promote TGFβ1-induced
EMT of ovarian cancer cells. Cancer Cell Int.
18(145)2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gao Y, Meng H, Liu S, Zhang Y, Jiao T, Liu
Y, Ou J, Wang D, Yao L, Liu S and Hui N: LncRNA-HOST2 regulates
cell biological behaviors in epithelial ovarian cancer through a
mechanism involving microRNA let-7b. Hum Mol Genet. 24:841–852.
2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li XX and Yu Q: Linc01094 accelerates the
growth and metastatic-related traits of glioblastoma by sponging
miR-126-5p. Onco Targets Ther. 13:9917–9928. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Xu H, Wang X, Wu J, Ji H, Chen Z, Guo H
and Hou J: Long non-coding RNA LINC01094 promotes the development
of clear cell renal cell carcinoma by upregulating SLC2A3 via
MicroRNA-184. Front Genet. 11(562967)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jiang Y, Li W, Yan Y, Yao X, Gu W and
Zhang H: LINC01094 triggers radio-resistance in clear cell renal
cell carcinoma via miR-577/CHEK2/FOXM1 axis. Cancer Cell Int.
20(274)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Xu J, Zhang P, Sun H and Liu Y:
LINC01094/miR-577 axis regulates the progression of ovarian cancer.
J Ovarian Res. 13(122)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mishra S, Yadav T and Rani V: Exploring
miRNA based approaches in cancer diagnostics and therapeutics. Crit
Rev Oncol Hematol. 98:12–23. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jeffries J, Zhou W, Hsu AY and Deng Q:
miRNA-223 at the crossroads of inflammation and cancer. Cancer
Lett. 451:136–141. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hetta HF, Zahran AM, Shafik EA, El-Mahdy
RI, Mohamed NA, Nabil EE, Esmaeel HM, Alkady OA, Elkady A, Mohareb
DA, et al: Circulating miRNA-21 and miRNA-23a expression signature
as potential biomarkers for early detection of non-small-cell lung
cancer. Microrna. 8:206–215. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Huang H, Huang S, Liang G, Zeng L, Pan J,
Yang W, Chen H, Liu J and Pan B: Comparison of kidney-tonifying and
blood-activating medicinal herbs vs NSAIDs in patients with knee
osteoarthritis: A protocol for a systematic review and
meta-analysis. Medicine (Baltimore). 99(e19370)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhang L, Tong Z, Sun Z, Zhu G, Shen E and
Huang Y: miR-25-3p targets PTEN to regulate the migration,
invasion, and apoptosis of esophageal cancer cells via the PI3K/AKT
pathway. Biosci Rep. 40(BSR20201901)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Huang L, Tang X, Shi X and Su L:
miR-532-5p promotes breast cancer proliferation and migration by
targeting RERG. Exp Ther Med. 19:400–408. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Song X, Wang Z, Jin Y, Wang Y and Duan W:
Loss of miR-532-5p in vitro promotes cell proliferation and
metastasis by influencing CXCL2 expression in HCC. Am J Transl Res.
7:2254–2261. 2015.PubMed/NCBI
|
|
27
|
Zhou Y, Zheng X, Lu J, Chen W, Li X and
Zhao L: Ginsenoside 20(S)-Rg3 inhibits the Warburg effect via
modulating DNMT3A/miR-532-3p/HK2 pathway in ovarian cancer cells.
Cell Physiol Biochem. 45:2548–2559. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen N and Wang J: Wnt/β-catenin signaling
and obesity. Front Physiol. 9(792)2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Huang P, Yan R, Zhang X, Wang L, Ke X and
Qu Y: Activating Wnt/β-catenin signaling pathway for disease
therapy: Challenges and opportunities. Pharmacol Ther. 196:79–90.
2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Gu C, Cai J, Xu Z, Zhou S, Ye L, Yan Q,
Zhang Y, Fang Y, Liu Y, Tu C, et al: miR-532-3p suppresses
colorectal cancer progression by disrupting the ETS1/TGM2
axis-mediated Wnt/β-catenin signaling. Cell Death Dis.
10(739)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Li X, Zheng P, Ji T, Tang B, Wang Y and
Bai S: LINC00052 ameliorates acute kidney injury by sponging
miR-532-3p and activating the Wnt signaling pathway. Aging (Albany
NY). 13:340–350. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Krishnamurthy N and Kurzrock R: Targeting
the Wnt/beta-catenin pathway in cancer: Update on effectors and
inhibitors. Cancer Treat Rev. 62:50–60. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Jia XX, Zhu TT, Huang Y, Zeng XX, Zhang H
and Zhang WX: Wnt/β-catenin signaling pathway regulates asthma
airway remodeling by influencing the expression of c-Myc and cyclin
D1 via the p38 MAPK-dependent pathway. Exp Ther Med. 18:3431–3438.
2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Grunewald T and Ledermann JA: Targeted
therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:139–152. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Słomian GJ, Nowak D, Buczkowska M,
Głogowska-Gruszka A, Słomian SP, Roczniak W, Janyga S and Nowak P:
The role of adiponectin and leptin in the treatment of ovarian
cancer patients. Endokrynol Pol. 70:57–63. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lambertini M, Horicks F, Del Mastro L,
Partridge AH and Demeestere I: Ovarian protection with
gonadotropin-releasing hormone agonists during chemotherapy in
cancer patients: From biological evidence to clinical application.
Cancer Treat Rev. 72:65–77. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Gao P and Wei GH: Genomic Insight into the
role of lncRNA in cancer susceptibility. Int J Mol Sci.
18(1239)2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Qiu JJ, Lin YY, Ye LC, Ding JX, Feng WW,
Jin HY, Zhang Y, Li Q and Hua KQ: Overexpression of long non-coding
RNA HOTAIR predicts poor patient prognosis and promotes tumor
metastasis in epithelial ovarian cancer. Gynecol Oncol.
134:121–128. 2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wang P, Liu X, Han G, Dai S, Ni Q, Xiao S
and Huang J: Downregulated lncRNA UCA1 acts as ceRNA to adsorb
microRNA-498 to repress proliferation, invasion and epithelial
mesenchymal transition of esophageal cancer cells by decreasing
ZEB2 expression. Cell Cycle. 18:2359–2376. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Booy EP, McRae EK, Koul A, Lin F and
McKenna SA: The long non-coding RNA BC200 (BCYRN1) is critical for
cancer cell survival and proliferation. Mol Cancer.
16(109)2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Cai S, Zhang P, Dong S, Li L, Cai J and Xu
M: Downregulation of SPINK13 promotes metastasis by regulating uPA
in ovarian cancer cells. Cell Physiol Biochem. 45:1061–1071.
2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Yu G, Wang W, Deng J and Dong S: LncRNA
AWPPH promotes the proliferation, migration and invasion of ovarian
carcinoma cells via activation of the Wnt/β-catenin signaling
pathway. Mol Med Rep. 19:3615–3621. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Yang Q, Yu Y, Sun Z and Pan Y: Long
non-coding RNA PVT1 promotes cell proliferation and invasion
through regulating miR-133a in ovarian cancer. Biomed Pharmacother.
106:61–67. 2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhu B, Liu W, Liu H, Xu Q and Xu W:
LINC01094 down-regulates miR-330-3p and enhances the expression of
MSI1 to promote the progression of glioma. Cancer Manag Res.
12:6511–6521. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Wang QY, Peng L, Chen Y, Liao LD, Chen JX,
Li M, Li YY, Qian FC, Zhang YX, Wang F, et al: Characterization of
super-enhancer-associated functional lncRNAs acting as ceRNAs in
ESCC. Mol Oncol. 14:2203–2230. 2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Zhang Y, Xu Y, Feng L, Li F, Sun Z, Wu T,
Shi X, Li J and Li X: Comprehensive characterization of lncRNA-mRNA
related ceRNA network across 12 major cancers. Oncotarget.
7:64148–64167. 2016.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Liu Q, Guo X, Que S, Yang X, Fan H, Liu M,
Li X and Tang H: LncRNA RSU1P2 contributes to tumorigenesis by
acting as a ceRNA against let-7a in cervical cancer cells.
Oncotarget. 8:43768–43781. 2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Jiang Y, Zhang H, Li W, Yan Y, Yao X and
Gu W: FOXM1-activated LINC01094 promotes clear cell renal cell
carcinoma development via microRNA 224-5p/CHSY1. Mol Cell Biol.
40:e00357–19. 2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Bian L, Zhi X, Ma L, Zhang J, Chen P, Sun
S, Li J, Sun Y and Qin J: Hsa_circRNA_103809 regulated the cell
proliferation and migration in colorectal cancer via
miR-532-3p/FOXO4 axis. Biochem Biophys Res Commun. 505:346–352.
2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Jiang W, Zheng L, Yan Q, Chen L and Wang
X: miR-532-3p inhibits metastasis and proliferation of non-small
cell lung cancer by targeting FOXP3. J BUON. 24:2287–2293.
2019.PubMed/NCBI
|
|
52
|
Zhang JX, Chen ZH, Chen DL, Tian XP, Wang
CY, Zhou ZW, Gao Y, Xu Y, Chen C, Zheng ZS, et al:
LINC01410-miR-532-NCF2-NF-kB feedback loop promotes gastric cancer
angiogenesis and metastasis. Oncogene. 37:2660–2675.
2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Huang K, Fan WS, Fu XY, Li YL and Meng YG:
Long noncoding RNA DARS-AS1 acts as an oncogene by targeting
miR-532-3p in ovarian cancer. Eur Rev Med Pharmacol Sci.
23:2353–2359. 2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Cuesta S, Batuecas J, Severin MJ, Funes A,
Rosso SB and Pacchioni AM: Role of Wnt/β-catenin pathway in the
nucleus accumbens in long-term cocaine-induced neuroplasticity: A
possible novel target for addiction treatment. J Neurochem.
140:114–125. 2017.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Routledge D and Scholpp S: Mechanisms of
intercellular Wnt transport. Development.
146(dev176073)2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Bełdowski M: Assessment of plasma
B-catenin concentration as biomarker of thyroid cancer. Pol Przegl
Chir. 87:340–345. 2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Zhang C, Zhang Z, Zhang S, Wang W and Hu
P: Targeting of Wnt/β-catenin by anthelmintic drug pyrvinium
enhances sensitivity of ovarian cancer cells to chemotherapy. Med
Sci Monit. 23:266–275. 2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Jiang K, Zhi XH, Ma YY and Zhou LQ: Long
non-coding RNA TOB1-AS1 modulates cell proliferation, apoptosis,
migration and invasion through miR-23a/NEU1 axis via Wnt/b-catenin
pathway in gastric cancer. Eur Rev Med Pharmacol Sci. 23:9890–9899.
2019.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Yu B, Ye X, Du Q, Zhu B, Zhai Q and Li XX:
The long non-coding RNA CRNDE promotes colorectal carcinoma
progression by competitively binding miR-217 with TCF7L2 and
enhancing the Wnt/β-catenin signaling pathway. Cell Physiol
Biochem. 41:2489–2502. 2017.PubMed/NCBI View Article : Google Scholar
|
|
60
|
da Silva LFI, Da Broi MG, da Luz CM, da
Silva LECM, Ferriani RA, Meola J and Navarro PA: miR-532-3p: A
possible altered miRNA in cumulus cells of infertile women with
advanced endometriosis. Reprod Biomed Online. 42:579–588.
2021.PubMed/NCBI View Article : Google Scholar
|
